Brachytherapy for the treatment recurrence prostate cancer after radical prostatectomy. A phase II trial

被引：0
|
作者：
Gomez Veiga, F. [1 ]
Gomez, I [1 ]
Castelo, L. [1 ]
Pertega, S. [2 ]
Marino, A. [3 ]
Fernandez, C. [3 ]
Candal, A. [3 ]
Casas, J. [4 ]
Zarraonaindia, A. [4 ]
Pita, S. [2 ]
Abal, V [2 ]
机构：
[1] Univ Hosp, Dept Urol, La Coruna, Spain
[2] Univ Hosp, Dept Stat, La Coruna, Spain
[3] COG, La Coruna, Spain
[4] Univ Hosp, Dept Urolgy, La Coruna, Spain
来源：
EUROPEAN UROLOGY SUPPLEMENTS | 2012年 / 11卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E414 / U909
页数：2
相关论文
共 50 条
  • [1] HDR brachytherapy and radiotherapy as salvage treatment for macroscopic recurrence in the prostate bed after radical prostatectomy.
    Guix, Benjamin
    Panichi, Marco
    Garcia, Ivan
    Gonzalez, Emma
    Najjari, Dina
    Guix, Ines
    Costa, Fernando
    Maria Sole, Josep
    Guix, Teresa
    Quinzanos, Luis
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [2] Radical salvage prostatectomy. Treatment of local recurrence of prostate cancer after radiotherapy
    Heidenreich, A.
    Semrau, R.
    Thueer, D.
    Pfister, D.
    [J]. UROLOGE, 2008, 47 (11): : 1441 - 1446
  • [3] AXIN2 and prostate cancer recurrence after radical prostatectomy.
    Hu, Brian Robin
    Fairey, Adrian Stuart
    Yang, Dongyun
    Li, Meng
    Groshen, Susan G.
    Stephens, Craig
    Quinn, David I.
    Kim, Philip
    Virk, Navneet
    Wang, Lina
    Martin, Sue Ellen
    Gill, Inderbir S.
    Goldkorn, Amir
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [4] LOW DOSE BRACHYTHERAPY WITH I125 IN PATIENTS WITH LOCAL PROSTATE CANCER RECURRENCE AFTER RADICAL PROSTATECTOMY.
    Gomez Veiga, F. G.
    Gomez, Marino A., I
    Castelo, L. A.
    Gonzalez, Dacal J.
    Lopez, D.
    Ponce, J.
    Candal, A.
    Chantada, V
    [J]. JOURNAL OF UROLOGY, 2010, 183 (04): : E232 - E232
  • [5] A phase II trial of celecoxib in PSA recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.
    Pruthi, RS
    Derksen, E
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 405S - 405S
  • [6] Predicting prostate cancer specific mortality following biochemical recurrence after radical prostatectomy.
    Freedland, SJ
    Humphreys, EB
    Mangold, LA
    Eisenberger, M
    Walsh, PC
    Partin, AW
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 389S - 389S
  • [7] Combined teletherapy and brachytherapy in local recurrence of prostate cancer after radical prostatectomy
    Niehoff, P
    Nürnberg, N
    Egberts, J
    Galalae, R
    Kimmig, B
    Kovács, G
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2004, 180 : 116 - 116
  • [8] Serum biomarkers for assessing risk of prostate cancer recurrence after radical retropubic prostatectomy.
    Zhang, Zhen
    Ronsenzweig, C. Nicole
    Sokoll, Lorr J.
    Cheli, Carol
    Bartsch, Georg
    Babaian, Richard J.
    Horninger, Wolfgang
    Fritsche, Herbert A.
    Taneja, Samir
    Lepor, Herbert
    Childs, Stacey J.
    Stamey, Thomas A.
    Brawer, Michael
    Partin, Alan W.
    Fung, Eric T.
    Chan, Daniel W.
    [J]. CANCER RESEARCH, 2006, 66 (08)
  • [9] A randomized phase II trial of neoadjuvant chemokine modulation in patients with localized prostate cancer undergoing radical prostatectomy.
    Jatwani, Karan
    Kalathil, Suresh
    Slomba, Ronald
    Farmer, Bailey
    Attwood, Kristopher
    Roy, Arya Mariam
    Singh, Prashant
    Kauffman, Eric
    Gopalakrishnan, Dharmesh
    George, Saby
    Levine, Ellis Glenn
    Guru, Khurshid
    Kalinski, Pawel
    Chatta, Gurkamal S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL)
  • [10] A randomized phase II trial of neoadjuvant chemokine modulation in patients with localized prostate cancer undergoing radical prostatectomy.
    Jatwani, Karan
    Farmer, Bailey
    Roy, Arya Mariam
    Slomba, Ronald
    Attwood, Kristopher
    Levine, Ellis Glenn
    Kauffman, Eric
    Kalinski, Pawel
    Guru, Khurshid
    Gopalakrishnan, Dharmesh
    Chatta, Gurkamal S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
12345